CD27 and renal cell carcinoma: Treatment of 25 (Melanoma, CRC, OC, PC, RCC, NSCLC) and 31 patients (melanoma, RCC), with varlilumab (alias: CDX-1127), a fully humanised agonistic CD27 IgG1 mAb, in a phase 1 dose-escalation and -expansion trial, respectively was well tolerated (166).